|
|
|
| The Effect of Zishen Runfeifang in Combined with Chemotherapy on Clinical Efficacy with Advanced Lung Cancer Exhibiting Both Qi and Yin Deficiencies |
| XU Huazhi, LI Ning, MA Yijie |
| Department of Oncology, Guishi County Traditional Chinese Medicine Hospital, Xinyang Henan 465200 |
|
|
|
|
Abstract 【Objective】To explore the efficacy of Zishen Runfeifang in combined with chemotherapy in patients with advanced lung cancer exhibiting both Qi and Yin deficiencies.【Methods】Eighty patients with advanced lung cancer exhibiting both Qi and Yin deficiencies, who received treatment in our two hospitals, were randomly divided into a chemotherapy group and a combination group, with 40 patients in each group. The chemotherapy group received conventional lung cancer chemotherapy, while the combination group received Zishen Runfeifang orally in addition to the chemotherapy. The efficacy, time to disease progression (TTP), 1-year survival rate, 1-year progression-free survival (PFS) rate, improvements in Traditional Chinese Medicine symptom scores, and Karnofsky Performance Scale (KPS) scores before and after treatment, as well as the occurrence of bone marrow suppression, were compared between the two groups.【Results】The total effective rate (RR) in the combination group was 37.5% (15/40) and the disease control rate (DCR) was 82.5% (33/40), whereas the chemotherapy group had an RR of 27.5%(11/40) and a DCR of 70.0%(28/40). The differences between the groups were not statistically significant(P>0.05). The TTP in the chemotherapy group was 6.5(4.2-8.4) months, with a 1-year survival rate of 30.0%(12/40), and a 1-year PFS rate of 85.0%(34/40); the combination group had a TTP of 7.2(5.5-9.3) months, a 1-year survival rate of 35.0%(14/40), and a 1-year PFS rate of 87.5%(35/40). The differences between the two groups were not statistically significant(P>0.05). Compared to before treatment, both groups showed a significant reduction in Traditional Chinese Medicine symptom scores after treatment, with more significant reductions in the combination group(P<0.05). After treatment, the stability rate of KPS scores in the combination group was 90.00%(36/40), significantly higher than the 70.00%(28/40) in the chemotherapy group(P< 0.05). The total occurrence rate of bone marrow suppression in the combination group was 17.5%(7/40), lower than 42.5%(17/40) in the chemotherapy group.【Conclusion】Zishen Runfeifang combined with chemotherapy can effectively improve patients' quality of life and reduce the occurrence rate of bone marrow suppression.
|
|
Received: 20 October 2023
|
|
|
|
|
|
[1] 肖茜,许玲. 中药复方联合化疗药物/分子靶向药物治疗肺癌的研究进展[J].中医药导报,2021,27(10):138-141.
[2] 夏小健,张进科,黄蓓,等. 气血舒服散治疗晚期肺癌癌因性疲乏患者气血两虚证36例[J].环球中医药,2021,14(7):1332-1335.
[3] 刘庆春,王爱民,刘德传,等. 健脾益气中药联合化疗治疗晚期非小细胞肺癌临床疗效[J].临床军医杂志,2017,45(11):1186-1188.
[4] 舒君,陆兵,吕红,等. 扶正解毒抗癌方结合GP方案对晚期NSCLC患者疗效、骨髓抑制发生率及Pokemon、TK1水平的影响[J].四川中医,2020,38(12):79-83.
[5] 余嗣崇,王荣荣,许新举,等. 回生口服液、重组人血管内皮抑制素联合GP方案对晚期非小细胞肺癌患者的临床疗效[J].中成药,2021,43(7):1971-1973.
[6] 尹枭孟,吴君华,郭建英,等. 清肺化痰汤加减对老年晚期非小细胞肺癌(痰热郁肺证)的辅助化疗效果[J].中国药师,2022,25(8):1390-1393.
[7] 宋爱英,李沛育,高飞,等. 潞党参口服液防治气血两虚型肺癌化疗所致骨髓抑制临床观察[J].中国药业,2022,31(22):94-97.
[8] 芦希艳,姚家久,赵宁侠. 中医辨证辅助化疗治疗非小细胞肺癌的临床疗效及对患者免疫功能和预后的影响[J].癌症进展,2022,20(8):797-799.
[9] 焦丽静,李嘉旗,龚亚斌,等. 中医药联合辅助化疗对早期非小细胞肺癌术后患者舌象变化规律的影响[J].上海中医药杂志,2020,54(2):21-27.
[10] 吴心语,李和根. 中医扶正治疗肺癌对免疫调节作用的研究进展[J].世界中西医结合杂志,2022,17(8):1691-1696.
[11] 于弘,胡倩,周光飚. 肺癌中医证型与用药规律的研究[J].中成药,2022,44(7):2273-2278.
[12] 杨红星,林丽珠. 中医药调控肺癌免疫治疗的研究进展[J].医药导报,2022,41(6):853-857.
[13] 张潇潇,刘浩,李杰,等. 中医“治未病”思想在肺癌防治中的应用策略探讨[J].河北中医,2020,42(8):1257-1260.
[14] 任晓玲,马秋晓,王冰,等. 张琼运用标本兼治与五脏一体观治疗肺癌术后咳嗽[J].中医学报,2022,37(11):2374-2379. |
|
|
|
2024, Vol. 41 
